# CJC-1295 Dosage in the Research Literature | Safe CJC-1295

> CJC-1295 dosage as used in published studies: single subcutaneous doses of 30, 60 or 90 ug/kg in human PK trials, 2 ug in mice. Research context only — not a human recommendation.

Every figure here is a research dose from a cited study, described as it was administered. None of it is a human recommendation; CJC-1295 has no approved human use.

## What Doses Were Used in the Published Studies

CJC-1295 dosage in the controlled human record is narrow and specific. The two early-phase pharmacokinetic studies in healthy adults used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram of body weight [1][3]. Teichman and colleagues administered 30 and 60 ug/kg, single and multiple doses, and characterized the GH and IGF-1 response and the 5.8-to-8.1-day half-life [1]. Ionescu and Frohman used 60 and 90 ug/kg single doses to measure the pulse response [3].

The preclinical dosing is separate and not comparable to human use. In the GHRH-knockout mouse, 2 micrograms of CJC-1295 per dose, given once every 24 hours, normalized growth [4]. These are the doses that appear in peer-reviewed studies. They describe what was administered to volunteers and to animals under study conditions — they are not, and should not be read as, a human dosing recommendation. CJC-1295 is unapproved for human use and is handled as a research chemical.

## Why online "protocols" are a different category

The fixed-microgram figures that circulate online — typically 100 to 300 micrograms of no-DAC Modified GRF 1-29 or of a CJC-1295/ipamorelin pairing — are not derived from controlled human trials. The published human evidence is the per-kilogram pharmacokinetic dosing above [1][3]; the fixed-dose community protocols are a separate, unvalidated practice. This dossier reports the research doses and flags the gap, rather than reproducing protocol numbers as if they carried trial evidence.

The distinction is not pedantic. A per-kilogram dose used to characterize half-life in a monitored Phase 1 study and a fixed milligram-fraction repeated indefinitely from a forum are different things measured against different evidence — one is a documented research parameter, the other is not.

## Routes and handling, as studied

CJC-1295 is a peptide, so oral bioavailability is negligible — it would be digested before absorption. The route used across the human studies is subcutaneous injection, with intravenous dosing appearing in the early GRF(1-29) pharmacokinetic work [1][3]. In research handling, the lyophilized peptide is reconstituted with bacteriostatic water and kept refrigerated; its four substitutions confer protease resistance, and DAC conjugation confers the multi-day duration [2].

These handling notes describe laboratory practice for a research chemical. They are not human-use instructions, and nothing here establishes a safe human administration — that determination would require the controlled trials CJC-1295 has not undergone [8].

---

A civic-register dossier on the CJC-1295 record — what the literature establishes marked on the record, the safety gaps left openly blank, and the unapproved status posted plainly; no clinic behind the register and nothing here prescribed or sold.